ENLEOFEN BIO PTE LTD
Enleofen is a developer of bio technology designed for the treatment of fibro-inflammatory diseases.The company is developing innovative, safe and highly effective therapeutics that address today's biggest healthcare challenges, enabling customers to access first-in-class antibody therapeutics for the treatment of fibrotic human diseases.
ENLEOFEN BIO PTE LTD
Social Links:
Industry:
Biotechnology Medical Therapeutics
Founded:
2017-04-01
Address:
Singapore, Central Region, Singapore
Country:
Singapore
Website Url:
http://www.enleofen.com
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
0
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon WordPress Google Universal Analytics Wordpress Plugins
Similar Organizations
ART BioScience
ART BioScience specializes in mRNA therapeutics for the treatment of rare diseases.
Opsonix
Opsonix is a developer of a pathogen-extracting therapy designed to transform the treatment of bloodstream infections and sepsis.
Spinogenix
Spinogenix is a developer of a new class of therapeutics for neurodegenerative and psychiatric diseases.
Current Employees Featured
Founder
Investors List
Goodman Capital
Goodman Capital investment in Series A - Enleofen Bio Pte Ltd
Official Site Inspections
http://www.enleofen.com
- Host name: 239.212.155.104.bc.googleusercontent.com
- IP address: 104.155.212.239
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "Enleofen Bio Pte Ltd"
Home - Enleofen
Enleofen was founded as a spin-out from NHCS, SingHealth and Duke-NUS Medical School focused on developing new anti-fibrotic therapies.See details»
Enleofen Bio Pte Ltd - Crunchbase Company Profile & Funding
Enleofen is a developer of bio technology designed for the treatment of fibro-inflammatory diseases.The company is developing innovative, safe and highly effective therapeutics that …See details»
Boehringer Ingelheim Partners with Enleofen | BI US
BI & Enleofen Bio Pte. Ltd. announce the acquisition of rights to Enleofen’s preclinical interleukin-11 platform by BI to develop first-in-class therapies.See details»
News - Enleofen
Latest news on Enleofen. Enleofen was founded as a spin-out from NHCS, SingHealth and Duke-NUS Medical School focused on developing new anti-fibrotic therapies.See details»
Enleofen 2025 Company Profile: Valuation, Funding & Investors
Information on valuation, funding, cap tables, investors, and executives for Enleofen. Use the PitchBook Platform to explore the full profile.See details»
Enleofen Bio Pte Ltd - Funding, Financials, Valuation & Investors
Apr 4, 2017 Enleofen is a developer of bio technology designed for the treatment of fibro-inflammatory diseases.See details»
Contact - Enleofen
Enleofen was founded as a spin-out from NHCS, SingHealth and Duke-NUS Medical School focused on developing new anti-fibrotic therapies.See details»
Enleofen Bio - Company Profile - Tracxn
Jan 17, 2025 Enleofen Bio - Developer of therapies for treating fibro-inflammatory diseases. from 2 investors. Founded by Stuart Cook and Sebastian Schafer in the year 2017. Enleofen Bio …See details»
Enleofen Bio Pte Ltd. - Drug pipelines, Patents, Clinical trials
Explore Enleofen Bio Pte Ltd. with its drug pipeline, therapeutic area, technology platform, 1 news, Technology Platform:Monoclonal antibody, Drug:ENx-108A.See details»
Duke-NUS - MEDICUS June 2020
What does Enleofen’s recent deal mean for Singapore’s life science start-up scene? A small team of creative and committed innovators behind start-up biotechnology company, Enleofen, a spin …See details»
Boehringer Ingelheim partners with Enleofen to develop first-in …
Boehringer Ingelheim and Enleofen Bio Pte. Ltd. (Enleofen) announced the acquisition of worldwide exclusive rights to Enleofen's preclinical interleukin-11 (IL-11) platform by …See details»
Incorporation of Enleofen
Enleofen Bio Pte. Ltd. was founded as a spin-out from National Heart Centre Singapore (NHCS), SingHealth and Duke-NUS Medical School with Series A funding. Enleofen develops first-in …See details»
Boehringer Ingelheim Acquires Enleofen's Anti-IL-11 Therapies for...
Jan 14, 2020 Boehringer Ingelheim has acquired worldwide exclusive rights to Enleofen’s interleukin-11 (IL-11) platform for fibrotic diseases such as PF.See details»
Boehringer Ingelheim se asocia con Enleofen para el desarrollo de ...
Jan 16, 2020 Enleofen se fundó en 2017 como una compañía spin-out de la Escuela de Medicina del Centro Nacional del Corazón de Singapour, el SingHealth y el Duke-NUS, que …See details»
Enleofen announces ENx108A as clinical development candidate
Enleofen Bio Pte Ltd (“Enleofen”), a biotechnology company developing first-in-class therapeutics for the treatment of fibro-inflammatory human diseases, today announced ENx108A, a human …See details»
Local researchers working on cure for severe liver disease
One in three people here has non-alcoholic fatty liver disease, even if they are not obese. Duke-NUS Medical School, National Heart Centre Singapore and biotechnology company Enleofen …See details»
Boehringer Ingelheim : Partners with Enleofen to Develop First-in …
Jan 9, 2020 Boehringer Ingelheim and Enleofen Bio Pte. Ltd. (Enleofen) announced today the acquisition of worldwide exclusive rights to Enleofen’s preclinical interleukin-11 (IL-11) platform …See details»
Breakthrough discovery presents hope for treating fibrotic
A breakthrough discovery in the field of cardiovascular fibrosis research made at Duke-NUS Medical School (Duke-NUS) and National Heart Centre Singapore (NHCS) has been licensed …See details»
Interleukin 11 Identified as New Therapeutic Target for Idiopathic ...
Sep 25, 2019 SINGAPORE, Sept. 30, 2019 /PRNewswire/ -- Enleofen Bio ("Enleofen") today announced the publication of data showing that blocking a protein called interleukin-11 (IL11) …See details»
Interleukin 11 Identified as New Therapeutic Target for ... - Enleofen
Enleofen Bio (“Enleofen”) today announced the publication of data showing that blocking a protein called interleukin-11 (IL11) might treat a severe and fatal lung disease called idiopathic …See details»